Business

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

articleHinova Pharmaceuticals, Inc. Class AOctober 15, 20243/news/voluntary-disclosure-on-obtaining-the-notice-of-approval-for-clinical-trial-of-oral-protac-drug-hp568-tablets-in-the-treatment-of-erher2-advanced-breast-cancer
Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

About this update from Hinova Pharmaceuticals, Inc. Class A

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A